Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

December 01, 1995; 45 (12 Suppl 8) Updated Proceedings of the Second International Conference on the Varicella-Zoster Virus

Herpes zoster and quality of life

A self-limited disease with severe impact

Eva Lydick, Robert S. Epstein, David Himmelberger, C. Jo White
First published December 1, 1995, DOI: https://doi.org/10.1212/WNL.45.12_Suppl_8.S52
Eva Lydick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert S. Epstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Himmelberger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Jo White
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Herpes zoster and quality of life
A self-limited disease with severe impact
Eva Lydick, Robert S. Epstein, David Himmelberger, C. Jo White
Neurology Dec 1995, 45 (12 Suppl 8) S52-S53; DOI: 10.1212/WNL.45.12_Suppl_8.S52

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
88

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Although herpes zoster is a self-limited disease, usually resolving in under 2 months, the pain can be severe and intractable. This pain markedly interferes with the patient's ability to perform normal daily activities and with quality of life.

Methods.

This study enrolled 50 patients with herpes zoster from four multispecialty practices, two each from the east and west coasts of the United States. Mean age was 70 years (range, 54 to 94). Approximately one-half were enrolled within a week of the onset of pain or rash and 80% within 2 weeks of onset.

We collected information on demographics and comorbidities at baseline and data on the extent and site of the lesions weekly. Extent of lesions was determined by tracing the involved area for each patient and calculating the actual area (in cm2) by computer and digitizing pad. Questions on comorbidities were used to compute the Charlson Comorbidity Index, [1] a commonly used index of comorbidity that was originally developed as a predictor of mortality.

The Wisconsin Brief Pain Inventory (BPI) [2] was administered daily in the first week and weekly thereafter. The BPI is a short, simple questionnaire on pain which takes about 5 minutes to complete. There are four questions on pain over the past 24 hours. The patient is asked to score his worst pain, least pain, average pain, and pain right now, from 0 to 10-zero being no pain at all and 10 being "pain as bad as you can imagine.'' In addition, there is one question on the location of pain and seven questions on how the pain interferes with daily activities (also scored from 0 to 10).

The MOS SF-36, [3] a standard health-related quality-of-life questionnaire, was given every 2 weeks. The 36 questions of the SF-36 are divided into seven domains and a single general healthperception question. [3] A global question on self-reported health ("How do you rate your own health? Is it excellent, very good, good, fair, or poor?'') was also asked of each patient at baseline.

Results.

Table 1 shows the impact of pain on activities of daily living. In this table, a score of 3 or more represents interference with activities of daily living, and a score of 2 or less represents no interference. At a pain level of 3, only a few patients reported interference with activities. At 4, 20 to 30% of patients reported interference. And at a pain level of 9 and 10, almost all individuals reported interference on all activities, with certain activities like work and general activity being influenced more by pain, and others, such as walking and relationships with others, being less affected by pain.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1. Association between "worst pain'' score and some interference (score of 3 or more on a 10-point scale) with individual activities of daily living, as measured by the Wisconsin Brief Pain Inventory

Weekly mean scores for the seven domains of the SF-36 are shown in Table 2. Each individual's score has been normalized, with 0 being the least value and 100 indicating the highest level of functioning or the best quality of life. At study week 2 (third or fourth week of the episode), patients tended to report the worst quality of life for all domains. The effects of herpes zoster are particularly apparent in the domains of physical functioning, emotional functioning, and vitality. Four patients were discontinued from the study before week 8 because of no rash, no symptoms, and no pain. Thus, the values in Table 2 in weeks 4, 6, and 8 are biased slightly downward.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2. Mean domain scores on the SF-36 by week

The relationships between quality-of-life domain scores and a number of other variables were examined using multivariate linear regression. The dependent variables were the individual SF-36 domain scores at week 2. Pain, rash, response to the global health question, Comorbidity Index score, and age were entered as independent variables. Pain is that reported on week 2 for the "worst pain'' question of the BPI. Rash area is the maximum rash area at weeks 0, 1, or 2. The worst pain as reported by these patients was the most important determinant of self-reported quality of life for all domains. This variable alone explained 25% of the variance.

Discussion.

Herpes zoster, which is an episodic infectious disease, can have a devastating effect on quality of life, even though the individual is aware that in most cases it will resolve completely. At week 8, scores from the zoster patients rebounded to close to mean scores from the general US population of similar age in most domains except for role functioning-physical and role functioning-emotional. [4] However, during the peak of the episode, the impact of herpes zoster on quality of life is at least as great as that seen with chronic diseases such as congestive heart failure, diabetes, myocardial infarction, and clinical depression. [3] The symptom that leads to this profound quality-of-life change is the associated pain. Certainly, as the pain ameliorates, patients' self-reported health status and their ability to carry out daily activities rebound to age- and sex-specific values within the general population.

  • Copyright 1995 by Advanstar Communication Inc.

REFERENCES

  1. 1.↵
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
    OpenUrlPubMed
  2. 2.↵
    Daut RL, Cleeland CS, Flannery RC. Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases. Pain 1983;17:197-210.
    OpenUrlPubMed
  3. 3.↵
    Stewart AL, Hays RD, Ware JE Jr. The MOS short form general health survey: reliability and validity in a patient population. Med Care 1988;26:724-735.
    OpenUrl
  4. 4.↵
    Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1993.
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Methods.
    • Results.
    • Discussion.
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease

Dr. Rizwan S. Akhtar and Dr. Sarah Brooker

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Clinical and Ethical Challenges
    The challenging patient with varicella-zoster virus disease
    Maria A. Nagel, Don Gilden et al.
    Neurology: Clinical Practice, April 15, 2013
  • Views & Reviews
    The impact of neuropathic pain on health-related quality of life
    Review and implications
    Mark P. Jensen, Marci J. Chodroff, Robert H. Dworkin et al.
    Neurology, April 09, 2007
  • Articles
    The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy
    M. A. Nagel, B. Forghani, R. Mahalingam et al.
    Neurology, February 07, 2007
  • Article
    Targeted RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Temporal Arteries From Giant Cell Arteritis Cases Reveals Viral Signatures
    Andrew N. Bubak, Teresa Mescher, Michael Mariani et al.
    Neurology: Neuroimmunology & Neuroinflammation, September 07, 2021
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise